BioInfra바이오인프라
199730 · KOSDAQ · ₩199730 · 바이오인프라
₩1,640▲ ₩39 (2.44%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | — | — | ₩30B | ₩35B |
| Cost of sales | — | — | ₩21B | ₩21B |
| Gross profit | — | — | ₩9.6B | ₩14B |
| Operating income | — | — | ₩1.3B | ₩6.4B |
| Net income | −₩9.1B | −₩4B | ₩2B | ₩6.2B |
| Net income to shareholders | −₩9.1B | −₩4B | ₩2B | ₩6.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total assets | ₩35B | ₩41B | ₩47B | ₩33B |
| Current assets | ₩12B | ₩15B | ₩21B | ₩13B |
| Cash and equivalents | ₩2.1B | ₩4B | ₩11B | ₩7.4B |
| Total liabilities | ₩18B | ₩14B | ₩13B | ₩15B |
| Current liabilities | ₩18B | ₩9.2B | ₩8.5B | ₩6.4B |
| Total equity | ₩16B | ₩28B | ₩34B | ₩18B |
| Shareholders' equity | ₩16B | ₩28B | ₩34B | ₩18B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash from operations | −₩1.5B | ₩1.7B | ₩679M | ₩8.4B |
| Capital spending | ₩1.3B | ₩2.8B | ₩3.1B | ₩10B |
| Free cash flow | −₩2.8B | −₩1.1B | −₩2.4B | −₩1.9B |
| Dividends paid | ₩1.9B | −₩2.9B | — | — |
Consolidated where available. Amounts in won.
Also known as: BioInfra / 바이오인프라 / 199730 / KRX:199730
Source: KRX statistical information